drug
palopegteriparatide
Marketedupdated 5mo agoby Ascendis Pharma Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4Protein drug with a maximum clinical stage of Approval, with an approval for hypoparathyroidism.
all catalysts(2)
Trials studying palopegteriparatide
- phase3A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism
- phase3A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
- —A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)
- —A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
- —Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 9, 2029
~2.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (27)
- Nov 12, 2042formulationUS 12403182
- Nov 12, 2042formulationUS 12403182
- Nov 12, 2042formulationUS 12403182
- Sep 28, 2037method-of-use (U-3982)US 11590207
- Sep 28, 2037method-of-use (U-3982)US 11590207
- Sep 28, 2037method-of-use (U-3982)US 11590207
- Sep 28, 2037formulationUS 11759504
- Sep 28, 2037formulationUS 11759504
- Sep 28, 2037formulationUS 11759504
- Sep 28, 2037method-of-use (U-3982)US 11857603
- Sep 28, 2037method-of-use (U-3982)US 11857603
- Sep 28, 2037method-of-use (U-3982)US 11857603
- Sep 28, 2037compositionUS 11890326
- Sep 28, 2037compositionUS 11890326
- Sep 28, 2037compositionUS 11890326
- Sep 28, 2037compositionUS 11918628
- Sep 28, 2037compositionUS 11918628
- Sep 28, 2037compositionUS 11918628
- Sep 28, 2037method-of-use (U-3982)US 12295989
- Sep 28, 2037method-of-use (U-3982)US 12295989
- Sep 28, 2037method-of-use (U-3982)US 12295989
- Sep 28, 2037method-of-use (U-3982)US 12453778
- Sep 28, 2037method-of-use (U-3982)US 12453778
- Sep 28, 2037method-of-use (U-3982)US 12453778
- Apr 30, 2031compositionUS 89068474.6y
- Apr 30, 2031compositionUS 89068474.6y
- Apr 30, 2031compositionUS 89068474.6y
FDA exclusivities (6)
- Aug 9, 2031ODE-492Orphan Drug (7y)4.8y
- Aug 9, 2031ODE-492Orphan Drug (7y)4.8y
- Aug 9, 2031ODE-492Orphan Drug (7y)4.8y
- Aug 9, 2029NCENew Chemical Entity (5y)2.8y
- Aug 9, 2029NCENew Chemical Entity (5y)2.8y
- Aug 9, 2029NCENew Chemical Entity (5y)2.8y
News(1)
- Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with AscendisNovo’s attempted rebrand got off to a shaky start this week with the news that the pharma had walked away from a $285 million biobucks pact to develop a monthly weight loss drug after less than two…fiercebiotech · 18d ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that